intraperiton cisplatin cytarabin treatment refractori recurr ovarian carcinoma preclin evalu impress concentration-depend cytotox synergi cisplatin cytarabin ovarian carcinoma clinic relev observ patient refractori recurr ovarian carcinoma phase II trial intraperiton IP cisplatin cours cytarabin mg cours treatment day maximum monthli cours surgic reevalu patient clinic evid diseas regimen secondari develop sever thrombocytopenia cours platelet addit toxic abdomin pain moder time therapi patient evid infect bacteri periton patient surgic reassess fourteen confid interv CI assess patient defin respons CI patient tumor nodul cm diamet CI patient lesion cm CI complet respons cr patient cm diseas none patient tumor nodul IP cisplatin/cytarabin result high respons rate patient minim residu ovarian carcinoma activ low patient bulki intraabdomin diseas 